Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Australia's Immuron gains on record quarterly diarrhoea drug sales

** Shares of Australian biopharmaceutical co Immuron Ltd
 IMC.AX  rise as much as 13.3% to A$0.085 in their biggest
intraday pct gain since Sept. 13
    ** IMC hits its highest level since Sept. 13
    ** Co says sales of Travelan, its digestive health immune
supplement, increased to a record A$1.3 mln ($835,770) in the
first quarter vs A$25,565 in Q1 FY23
    ** Anticipates continued demand for replenishment of
Travelan, as retail pharmacies sell to consumers - IMC
    ** Nearly 189,200 shares change hands by 0253 GMT, vs 30-day
average volume of 59,912
    ** Stock down 12.8% YTD, as of last close

($1 = 1.5555 Australian dollars)

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))

Recent news on Immuron

See all news